Browsing Tag
Lynkuet
4 posts
Bayer (ETR: BAYN) Q1 beat lifts shares as Supreme Court Roundup ruling looms
Bayer just beat Q1 consensus by 19%. But the bigger question is whether the Supreme Court hands the company its Roundup endgame in six weeks.
FDA approves Bayer’s Lynkuet, a first-in-class dual NK-1/NK-3 antagonist for menopausal hot flashes
Find out how Bayer’s Lynkuet is changing menopause care with the first dual-neurokinin receptor antagonist approved by the FDA for hot flashes!
Bayer’s FDA review extension for elinzanetant signals global push for hormone-free menopause therapies
Bayer receives FDA review extension for elinzanetant menopause drug; U.S. approval still likely, with global rollout underway and analysts optimistic.
MHRA approves Bayer’s Lynkuet as first non-hormonal treatment for menopause hot flushes
Bayer’s Lynkuet becomes the world’s first approved non-hormonal menopause pill. Find out what MHRA’s decision means for women’s health today.